News articles about Foundation Medicine (NASDAQ:FMI) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Foundation Medicine earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.1799286669578 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- BRIEF-Foundation Medicine – Co, Guardant Health Announced Agreement To Settle False Advertising Challenges (reuters.com)
- Foundation Medicine and Guardant Health Agree to Resolve False Advertising Lawsuit (finance.yahoo.com)
- HIGH PROFILE: Tjuana Byrd, new president of Women’s Foundation of Arkansas (arkansasonline.com)
- 2017 Banfield Pet Hospital® Corporate Social Responsibility Report and 2017 Banfield Foundation® Impact Report Released (bizjournals.com)
- Foundation Medicine (FMI) Q4 2017 Earnings Conference Call Transcript (finance.yahoo.com)
Foundation Medicine (NASDAQ:FMI) traded down $1.05 during trading hours on Wednesday, hitting $79.00. The company had a trading volume of 313,407 shares, compared to its average volume of 303,765. The firm has a market capitalization of $2,860.00, a PE ratio of -17.52 and a beta of -0.21. Foundation Medicine has a 12-month low of $29.90 and a 12-month high of $87.10. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.67 and a current ratio of 1.86.
A number of equities analysts recently weighed in on FMI shares. BidaskClub raised Foundation Medicine from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Zacks Investment Research raised Foundation Medicine from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a report on Wednesday, December 6th. Wells Fargo & Co reissued a “market perform” rating and set a $80.00 target price (up previously from $67.00) on shares of Foundation Medicine in a report on Thursday, March 8th. Goldman Sachs Group started coverage on Foundation Medicine in a report on Monday, January 29th. They set a “neutral” rating and a $73.00 target price for the company. Finally, Cowen initiated coverage on Foundation Medicine in a report on Thursday, February 15th. They set an “outperform” rating and a $90.00 target price for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. Foundation Medicine has an average rating of “Buy” and an average price target of $69.60.
In related news, CFO Jason Ryan sold 2,336 shares of Foundation Medicine stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $64.00, for a total value of $149,504.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Troy Cox sold 26,713 shares of Foundation Medicine stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $70.13, for a total value of $1,873,382.69. Following the completion of the transaction, the chief executive officer now owns 224,345 shares of the company’s stock, valued at $15,733,314.85. The disclosure for this sale can be found here. Insiders sold 276,452 shares of company stock valued at $18,699,403 over the last quarter. 2.70% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/03/14/foundation-medicine-fmi-receives-daily-news-sentiment-rating-of-0-13/1890333.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.